Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$324.04 -0.6%	$288.10	$205.87 ▼ $327.21	$42.23B	0.22	858,694 shs	637,387 shs
BGNE BeiGene		$194.32	$142.00 ▼ $248.16	$18.03B	0.57	331,553 shs	331,608 shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
RPRX Royalty Pharma	$35.70 -0.9%	$33.55	$24.05 ▼ $36.33	$20.10B	0.48	3.66 million shs	1.56 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.01%	+4.14%	+7.06%	+27.50%	+34.19%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+29.47%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
RPRX Royalty Pharma	+0.45%	+1.78%	+8.98%	+15.59%	+36.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.2615 of 5 stars	2.4	4.0	0.0	4.3	3.9	2.5	0.6
BGNE BeiGene	1.3348 of 5 stars	3.4	0.0	0.0	0.0	0.0	0.8	0.6
HZNP Horizon Therapeutics Public	1.218 of 5 stars	0.0	0.0	0.0	3.2	0.6	1.7	1.9
RPRX Royalty Pharma	4.9035 of 5 stars	3.6	1.0	3.3	3.7	3.9	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$340.00	4.92% Upside
BGNE BeiGene	2.83	Moderate Buy	$253.92	∞ Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.25	Buy	$47.33	32.59% Upside

Current Analyst Ratings Breakdown

Latest ALNY, HZNP, BGNE, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/2/2025	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $349.00
5/2/2025	ALNY Alnylam Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$300.00 ➝ $325.00
4/11/2025	ALNY Alnylam Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$284.00 ➝ $268.00
4/9/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00
4/2/2025	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.79	N/A	N/A	$0.52 per share	623.16
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
RPRX Royalty Pharma	$2.26B	8.87	$4.18 per share	8.55	$17.56 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	364.09	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
RPRX Royalty Pharma	$858.98M	$1.85	19.32	7.35	1.84	48.23%	24.71%	13.87%	8/6/2025 (Estimated)

Latest ALNY, HZNP, BGNE, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.46%	N/A	47.57%	5 Years

Latest ALNY, HZNP, BGNE, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
BGNE BeiGene	0.05	1.93	1.72
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
RPRX Royalty Pharma	0.68	1.56	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BGNE BeiGene	48.55%
HZNP Horizon Therapeutics Public	80.37%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.20%
BGNE BeiGene	7.43%
HZNP Horizon Therapeutics Public	2.20%
RPRX Royalty Pharma	18.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.82 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
RPRX Royalty Pharma	80	562.24 million	455.98 million	Optionable

ALNY, HZNP, BGNE, and RPRX Headlines

Recent News About These Companies

Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline

July 1 at 5:49 AM | seekingalpha.com

Investors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past year

June 29 at 12:43 PM | finance.yahoo.com

Royalty Pharma PLC (NASDAQ:RPRX) Holdings Raised by Robeco Institutional Asset Management B.V.

June 29 at 4:16 AM | marketbeat.com

Asset Management One Co. Ltd. Acquires 12,148 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

June 29 at 3:44 AM | marketbeat.com

Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold

June 29 at 3:22 AM | marketbeat.com

RPRX Royalty Pharma plc - Seeking Alpha

June 28 at 1:18 PM | seekingalpha.com

Royalty Pharma plc (RPRX) Balance Sheet - Yahoo Finance

June 28 at 1:18 PM | finance.yahoo.com

Royalty Pharma PLC (NASDAQ:RPRX) Holdings Decreased by Overbrook Management Corp

June 28 at 8:03 AM | marketbeat.com

Royalty Pharma plc - Ordinary Shares - Class A RPRX Overview

June 28 at 7:57 AM | money.usnews.com

Marathon Asset Management Ltd Sells 68,924 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

June 28 at 7:32 AM | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Paragon Capital Management Inc.

June 27, 2025 | marketbeat.com

31,200 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Board of the Pension Protection Fund

June 27, 2025 | marketbeat.com

2 Surging Stocks to Research Further and 1 to Be Wary Of

June 26, 2025 | finance.yahoo.com

Phillips Wealth Planners LLC Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)

June 26, 2025 | marketbeat.com

Moran Wealth Management LLC Buys Shares of 88,991 Royalty Pharma PLC (NASDAQ:RPRX)

June 26, 2025 | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Buys New Stake in Royalty Pharma PLC (NASDAQ:RPRX)

June 26, 2025 | marketbeat.com

Kentucky Retirement Systems Invests $819,000 in Royalty Pharma PLC (NASDAQ:RPRX)

June 26, 2025 | marketbeat.com

Royalty Pharma Enters Into Upto $2 Bln Funding Deals With Revolution Medicines - Nasdaq

June 25, 2025 | nasdaq.com

RPRX - Royalty Pharma PLC Class A Chart - Morningstar

June 24, 2025 | morningstar.comM

Royalty Pharma deal gives Revolution access to $2 billion in financing

June 24, 2025 | thepharmaletter.comT

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

June 24, 2025 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALNY, HZNP, BGNE, and RPRX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$324.04 -2.05 (-0.63%)

As of 01:02 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$35.70 -0.33 (-0.92%)

As of 01:02 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time